Sellas Life Sciences
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -9,605 | -8,407 | -7,658 | 292 |
EBIT | -10,629 | -9,252 | -8,255 | -6,791 |
Net Income | -9,605 | -8,407 | -7,658 | -6,791 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,588 | -8,846 | -4,921 | -7,068 |
Cash | 138,443 | 107,197 | 71,893 | 44,420 |
Basic Shares | 189,183 | 172,481 | 153,103 | 108,396 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1,000 |
Gross Profit | 0 | 900 | ||
EBITDA | -26,863 | 632 | 529 | -31,493 |
EBIT | -28,274 | -30,881 | -37,340 | -31,950 |
Net Income | -26,863 | -30,881 | -37,340 | -41,301 |
Net Change In Cash | 0 | 0 | 0 | 1,000 |
Free Cash Flow | -28,389 | -35,402 | -36,910 | -28,309 |
Cash | 71,893 | 13,886 | 2,530 | 17,125 |
Basic Shares | 109,051 | 61,202 | 27,777 | 19,395 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.05 |
2026-03-31 | -$0.04 |
2025-12-31 | -$0.05 |
2025-09-30 | -$0.06 |